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Neuropeptide Y (NPY) is an orexigenic neuropeptide that plays a role in regulating adiposity by promoting energy
storage in white adipose tissue and inhibiting brown adipose tissue activation in mammals. This review describes
mechanisms underlying NPY’s effects on adipose tissue energy metabolism, with an emphasis on cellular proliferation,
adipogenesis, lipid deposition, and lipolysis in white adipose tissue, and brown fat activation and thermogenesis. In
general, NPY promotes adipocyte differentiation and lipid accumulation, leading to energy storage in adipose tissue,
with effects mediated mainly through NPY receptor sub-types 1 and 2. This review highlights hypothalamus-
sympathetic nervous system-adipose tissue innervation and adipose tissue-hypothalamus feedback loops as pathways
underlying these effects. Potential sources of NPY that mediate adipose effects include the bloodstream, sympathetic
nerve terminals that innervate the adipose tissue, as well as adipose tissue-derived cells. Understanding the role of
central vs. peripherally-derived NPY in whole-body energy balance could shed light on mechanisms underlying the
pathogenesis of obesity. This information may provide some insight into searching for alternative therapeutic strategies
for the treatment of obesity and associated diseases.
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Obesity is defined as a state of increased adiposity result-
ing from chronic nutrient excess, where energy intake
significantly exceeds energy expenditure [1]. Energy in-
take is reflected by food intake and energy expenditure
can be affected by basal metabolism, physical activity,
and thermogenesis [2]. Dysregulation of either central or
peripheral signals may lead to a state of anorexia or
obesity. According to the Center for Disease Control in
2011–2012, more than one third of all U.S. adults are
considered to be overweight or obese and these numbers
are expected to continue to rise. The rise in obesity, a
predisposing factor for developing diabetes, hyperten-
sion, hyperlipidemia, cancer and other disorders, has
driven a major interest in the regulation of appetite, food
intake and fat accumulation [3]. Energy homeostasis is
governed by a complex neuroendocrine system including
appetite regulatory hypothalamic peptides, as well as* Correspondence: egilbert@vt.edu
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These signals act in a reciprocal manner to integrate in-
formation about energy status, a system referred to as
the hypothalamus-adipose tissue axis. The recognition of
the importance of the hypothalamus-adipose tissue axis
in energy balance has propelled studies aimed at under-
standing the roles of adipose- and hypothalamic-derived
peptides on energy intake, storage and expenditure.
One of the major regulators of energy intake, neuro-
peptide Y (NPY), has emerged as an important player in
the hypothalamus-adipose tissue axis. Neuropeptide Y, a
36 amino acid peptide, is one of the most potent orexi-
genic hypothalamic neuropeptides identified to date [4].
Depending on the anatomical location and the receptor
sub-type, NPY is also involved in other physiological
processes such as locomotion, learning and memory,
anxiety, epilepsy, circadian rhythm, and cardiovascular
function [3]. The goal of this review is to provide a more
in-depth and holistic understanding of the role of NPY
in energy homeostasis, bridge the gap between appetite/
central nervous system and adipose tissue/peripheralLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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future study directions. To emphasize the potential dual
roles of NPY in energy intake and energy storage/ex-
penditure, we highlight the idea of hypothalamus and
adipose tissue crosstalk and the connection to the sym-
pathetic nervous system. Numerous studies demonstrate
that NPY is a major mediator in promoting energy stor-
age, positing that it could serve as a potential biomarker
for obesity. Consistent with this hypothesis, the NPY re-
ceptor sub-type 5 (NPYR5) antagonist, velneperit, has
been recently explored in clinical testing as a potential
anti-obesity drug [5]. Therefore, a better understanding
of the mechanisms of how NPY influences body adipos-
ity may facilitate therapeutic interventions for obesity.
NPY and receptor sub-type tissue distribution
In the central nervous system (CNS), NPY is found in
highest concentration within the hypothalamus, brain
stem, and anterior pituitary. In the arcuate nucleus (ARC)
of the hypothalamus, NPY is highly expressed with
another orexigenic neuropeptide, agouti-related peptide
(AgRP), an endogenous melanocortin receptor 3 and 4
(MC3R and MC4R, respectively) antagonist [6]. The ARC
NPY neurons serve as a feeding center that senses and in-
tegrates peripheral energy signals, such as blood glucose
concentration, ghrelin, leptin and insulin, due to the
unique anatomic structure of the ARC in lacking a blood
brain barrier [7]. The synthesis and secretion of ARC NPY
is induced in response to energy deficiency and greater
metabolic demand such as increased exercise, cold and
pregnancy [8].
The NPY affects food intake by innervating with other
appetite regulatory factors in the CNS and regulates en-
ergy utilization via modulation of fat deposition and me-
tabolism. These functions are achieved by binding to
various NPY receptors (NPYRs) that are distributed across
the body, the most well-known being NPYR1, NPYR2,
and NPYR5, all of which are G protein coupled receptors
[9]. In situ hybridization assays on adult mouse brain sec-
tions revealed widespread distribution of NPYR1, while
NPYR2 and 5 displayed a more restricted pattern of ex-
pression [10]. The NPYR1 is considered to be most dir-
ectly involved in food intake and energy expenditure,
whereas the NPYR2 receptor is an autoreceptor that is
mainly expressed in the ARC, and can regulate food intake
and energy balance through modulation of endogenous
NPY release [11,12]. The NPYR1 has a high affinity for
the NPY analog [Leucine31, Proline34] and requires a
complete N terminus for binding. It has lower affinity for
NPY C-terminal fragments such as NPY13–36 and NPY3–36
[13]. The NPYR2 requires intact carboxyl-terminal frag-
ments for binding [14]. The preferred binding ligands, dis-
tribution of NPYRs, and NPY function in the CNS and
adipose tissue are summarized in Table 1.In the periphery, NPY is widely distributed in the sym-
pathetic nerves, the adrenal medulla, platelets, and vari-
ous cell types within white adipose tissue [26]. The
expression of NPY and NPYR2 can be induced in macro-
phages [29], platelets, nerves, and adipocytes by stress or
genetically- or high fat diet-induced obesity in mice
[29,30]. In human adipose tissue, NPY was detected in
mature adipocytes but not in preadipocytes [31]. Others
detected NPY mRNA in human subcutaneous and vis-
ceral fat [32] and murine adipocytes as well as various
cell types from adipose tissue stromal vascular fractions
(SVF) [29]. Increased expression of NPY in adipose tissue
appears to be a common feature of obesity in different
species. Abundance of NPY mRNA and protein was
greater in visceral fat (pooled mesenteric, omental and
retroperitoneal) of 21 day-old obese rats born from dams
that were fed a low-protein diet during gestation and lac-
tation, compared to controls [33]. There was also greater
NPY mRNA in visceral fat of obese Zucker rats compared
to their lean counterparts, and both an insulin analogue
and dexamethasone augmented NPY expression in lean
but not obese rats [33]. We reported greater expression of
NPY and NPYR1 and NPYR5 mRNA in the abdominal fat
of obese chickens compared to lean chickens [34].
The NPYR1, NPYR2 and NPYR5 have all been de-
tected in various cell types from different fat depots in
rodent models [29,35,36], although in one report NPYR5
was not detected by real time PCR in either adipocytes
or the SVF of adipose tissue from either lean or obese
mice [29] and in another only NPYR5 was detected in
sympathetic neuron/3 T3-L1 co-cultures [37]. Human and
mouse preadipocytes, adipocytes and endothelial cells ex-
press NPYR2 [30] and mouse NPYR1 expression was de-
tected in mouse preadipocytes and adipocytes [37]. Others
reported that NPYR1 mRNA was abundant in both rat
and mouse preadipocytes, whereas NPYR2 and NPYR5
were undetectable [33]. We demonstrated that NPY,
NPYR1, NPYR2 and NPYR5 mRNA were expressed in
chicken abdominal fat, albeit at lower quantities than in
the hypothalamus, with differential expression between
chickens selected for low or high body weight, and highly
negative heterosis, suggesting a role for the NPY system in
energy balance in chickens [34]. Thus, in a variety of ver-
tebrates, NPY and NPYR1, 2 and 5 are expressed in vari-
ous cell types in white adipose tissue.
Adipose tissue function and sympathetic nervous system
innervation
As the primary energy storage reservoir, adipose tissue
plays an important role in energy balance. It contains
two distinct types of fat tissue: white adipose tissue
(WAT) and brown adipose tissue (BAT). White adipose
tissue is specialized for the storage of chemical energy in
the form of triacylglycerol (TAG), while BAT dissipates
Table 1 Neuropeptide Y family receptors with preferred ligands, receptor distribution and function in food intake and fat deposition
Y1 Y2 Y4 Y5
Preferred ligand NPY NPY PP NPY
Requires a complete N terminus NPY3-36 NPY NPY2-36
Requires intact C-terminal fragments NPY3-36
Pre vs. post junctional
receptor






Cortex, brainstem, hippocampus, amygdala,
striatum, nucleus accumbens
Subnucleus gelatinosus of NTS,
dorsal motor nucleus of the vagus
Cortex, hippocampus, amygdala
Hypoth-alamus ARC, VMN, PVN, DMN, LH Supraoptic
nucleus
ARC, PVN, LH, medial preoptical area,
anterior hypothalamic nucleus
ARC, PVN PVN, ARC, VMN, DMN, LH
Perip-heral Thyroid, parathyroid glands,
heart, spleen and digestive
system, adipose tissue
Adipose tissue Skeletal muscle, small intestine,
pancreas, prostate, uterus, lung, colon
Adipose tissue
Types of manipulation/
Effects on food intake
and body weight
Y1 antagonist central injection/Reduced
food intake [15,16]; Y1 agonist central
injection/Increase food intake [17];
Y1KO/Developed obesity, increased
body fat, slight reduction in food
intake [18,19]
Y2 agonist IP injection/ inhibit food intake
[20]; Hypothalamus-specific Y2 KO/Increased
food intake and decreased body weight;
Germ-line Y2 KO/Reduced body weight and
adiposity, reduced food intake in males and
increased food intake in females [21]
Y4 KO/Decreased body weight, less
WAT, decreased 24-h food intake
in male mice [22]
Central administration of Y5 antisense
oligodeoxynucleotides/Reduced body
weight and a decrease in food intake
[23,24]; Y5 KO/ Mild late-onset obesity,
increased body weight, food intake
and adiposity [25]
Abbreviations: KO knock out, NTS Nucleus of the solitary tract, WAT white adipose tissue, ARC arcuate nucleus, PVN Paraventricular nucleus, VMN ventromedial nucleus, DMN dorsomedial nucleus, LH Lateral
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shivering thermogenesis. As will be discussed in this
review, major mechanisms for WAT expansion and turn-
over are changes in rates of adipocyte precursor cell pro-
liferation, differentiation of precursor cells into adipocytes
(adipogenesis), as well as changes in synthesis of fatty
acids (lipogenesis), TAGs, and hydrolysis of stored lipids
(lipolysis) to liberate glycerol and free fatty acids in the
adipocyte [38]. Unlike WAT, BAT dissipates chemical en-
ergy in the form of heat generation by means of uncoup-
ling protein 1 (UCP1) expression to uncouple respiration
in the mitochondria [2]. Increased BAT in animals was as-
sociated with a lean and healthy phenotype [39], whereas
loss of BAT was correlated with obesity and metabolic dis-
eases [40]. BAT is predominantly distributed in the inter-
scapular region of mammals. Although brown fat was
once considered only necessary in early neonates, recent
positron emission tomography scanning studies demon-
strated that this tissue is present and plays a pivotal role in
energy balance in adult humans [41,42]. Therefore, induc-
tion of BAT in humans offers the possibility of increasing
energy expenditure without necessarily causing dysfunc-
tion in other tissues, and is hence an obvious therapeutic
target for treating obesity.
White adipose tissue is a heterogeneous organ com-
prised of mature adipocytes, preadipocytes, mesenchy-
mal stem cells, immune cells, and a matrix of collagen
fibers that house numerous nerve endings and vascular
networks [43]. Thus, NPY can potentially affect WAT me-
tabolism through the neuroendocrine route, where it is
co-stored with norepinephrine (NE) and can be secreted
via sympathetic nervous system (SNS) innervation, auto-
crine mechanisms by mature adipocytes, paracrine path-
ways by immune cells [29], as well as endocrine routes by
platelets from the blood vessels, or across the blood brain
barrier [44]. Neuropeptide Y coexists within the nerve ter-
minal with NE and adenosine triphosphate in postgangli-
onic sympathetic nerve fibers throughout the body, and
can be co-released from the axon terminals in different
quantities depending on the stimulation intensity and the
pattern of sympathetic nerve activation [45,46]. Retro-
grade and anterograde fluorescence tract tracers were
used to reveal sympathetic innervation of adipose tissue
and that different fat depots were differentially innervated
(reviewed by [47]). As will be described later in this re-
view, the hypothalamus-SNS-WAT pathway provides a
plausible mechanism for how NPY exerts reciprocal func-
tions on energy intake via the hypothalamus and energy
storage and expenditure via WAT.
NPY promotes adipogenesis and inhibits lipolysis in
adipose tissue
NPY was shown to have hyperplasic, adipogenic and antil-
ipolytic effects in adipose tissue cells, and angiogeniceffects in the vasculature surrounding adipose cells (a
major contributor to adipose expansion) both in vitro and
in vivo [30,48], although in one study there was no effect
of NPY treatment on lipid accumulation in 3 T3-L1 cells
at 8 days post-differentiation [33]. Effects of NPY on adi-
pose tissue function were thought to occur mainly via
NPYR1- and NPYR2-mediated pathways, although NPYR5
has also been implicated in the cellular responses
[14,30,44,49,50]. Two weeks of cold exposure, combined
with consumption of a high-fat and high-sugar diet, was
associated with increased expression of NPY and NPYR2
in subcutaneous fat depots of mice, with expression local-
ized to blood vessels, nerves and adipocytes [30]. Condi-
tional knockdown of NPYR2 in only the peripheral tissues
(including adipose) of adult mice prevented high fat diet-
induced obesity [51]. In normal chow-fed mice, the knock-
down had no effect on food intake or body weight,
suggesting that NPYR2 plays an important role in energy
oxidation in peripheral tissues [51]. The NPYR2 germline
knock-out mice were not susceptible to cold stress-
induced augmentation of diet-induced obesity and treat-
ment of wild-type mice with a NPYR2 antagonist for
2 weeks via slow-release pellets delivered to the adipose
tissue reduced visceral fat depot mass by 40%. Similarly,
conditional knockdown of NPYR2 by an adenoviral vector
injected into the subcutaneous abdominal fat of mice led
to a 50% reduction in stress-induced fat expansion after
2 weeks [30]. These results collectively suggest that those
NPY-mediated effects on adipose tissue were occurring
mainly through NPYR2 [30]. Similarly, in immune-
deficient mice or rhesus monkeys that received subcutane-
ous injections of a 14-day slow-release NPY pellet, a ring
of new fat tissue appeared around the pellet, and was sus-
tained for at least 3 months, demonstrating the ability of
NPY to locally promote de novo fat formation [52].
Neuropeptide Y-mediated effects on fat were also demon-
strated with a translational application to reconstructive
surgery [52]. Freshly collected human adipose tissue was
transplanted into immune-deficient mice and effects of
NPY on fat graft survival and vascularity were assessed
[52]. Treatment with NPY enhanced long-term (3 month)
human fat graft survival and vascularity in the athymic
mice, whereas in mice that did not receive NPY pellet in-
jection, there was greater than 70% resorption of the
xenograft, a major concern with such transplantation
surgeries in humans [52]. Researchers showed that the
effects on fat pad mass were due to enhanced survival of
the human graft and not synthesis of new adipose tissue
by the host animal, illustrating a potential clinical appli-
cation of NPY.
In genetically obese (B6.V-Lepob/J) mice, plasma concen-
trations of NPY were more than 200% greater than wild-
type mice, and the obese mice also displayed greater
expression of NPY and NPYR2 mRNA in subcutaneous
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from adipose tissue [30]. Interestingly, in both obese and
lean wild-type mice, there was substantial adipose tissue
expansion as a result of treatment with NPY pellets (1 μg
per 14-day release pellet) delivered locally to the sub-
cutaneous abdominal fat [30]. These effects were blunted
when mice were injected with a pellet containing
BIIE0246, an NPYR2 antagonist (1 umol/day for 14 d),
with a decrease in fat mass accompanied by reduced vas-
cularity and increased apoptosis in the abdominal fat pads
[30]. Results from these studies implied that NPY’s actions
on adipose tissue include promotion of both adipogenesis
and angiogenesis, both mediated primarily through
NPYR2 [30].
Function through NPYR2 could be mediated through
enzymatic cleavage of the NPY peptide in adipose tissue
[48]. In one study, NPY and dipeptidyl peptidase –IV
(DPPIV) mRNA were detected in both 3 T3-L1 preadi-
pocytes and terminally differentiated adipocytes, and
treatment of preadipocytes with recombinant DPPIV
promoted differentiation of cells into adipocytes [48].
The DPPIV is known to cleave NPY into the NPYR2
agonist NPY3–36. Immunoneutralization of NPY or treat-
ment with a NPYR2 antagonist, but not NPYR1 or NPYR5
antagonists, blunted DPPIV’s adipogenic effects [48].
Treatment with NPY alone also promoted preadipocyte
differentiation and combined treatment of NPY with a
DPP-IV inhibitor , vildagliptin, blocked NPY’s adipogenic
effects, lending further support to the idea that DPP-IV
cleaves NPY in adipose tissue and thereby promotes adi-
pogenesis via NPYR2-mediated cell signaling [48].
Effects of NPY on TAG hydrolysis, on the other hand,
were shown to occur mainly through NPYR1, with effects
on lipolysis influenced by the nutritional state, other cellu-
lar factors, and genetic background of the animal. For ex-
ample, in cultured rat adipocytes, NPY dose-dependently
inhibited lipolysis, an effect that was blunted when the an-
imals were fasted for 48 hours prior to treatment [14].
Receptor-specific NPY fragments were used to show that
inhibition of lipolysis was mediated through NPYR1. In
visceral fat cells (but not subcutaneous) from rats that
were injected with 6-hydroxydopamine (OHDA) (a neuro-
toxin for sympathetic neurons that is used to chemically
ablate sympathetic nerves), lipolysis was increased and the
effects were shown to occur via NPYR2-mediated signal-
ing mechanisms [14]. Using receptor-specific peptide frag-
ments, it was shown that inhibition of lipolysis in adipose
tissue occurred through NPYR1 but not NPYR2, and that
the increase in lipolysis observed after sympathectomy and
treatment with a NPYR2-specific peptide could be due to
a switching of the receptor from Gi to Gs coupling [14].
Metabolic differences observed between subcutaneous
and visceral fat depots may be partly explained by differ-
ences in SNS innervation. In general, visceral fat inhumans is associated with adverse health outcomes,
whereas subcutaneous adipose tissue is considered to be
an energy storage reservoir that is relatively benign [38].
Recently, Nguyen et al. demonstrated that while there
was some overlap in central sympathetic neural circuits
between inguinal (subcutaneous) and mesenteric (vis-
ceral) fat in Siberian hamsters, there were more neurons
involved in innervating the inguinal fat pads, and inter-
estingly, food withdrawal induced a stronger sympathetic
drive to inguinal adipose tissue [53]. Thus, research on
NPY’s role in adipose tissue function should take into
consideration the differences in physiology between fat
depots in different anatomical locations under different
nutritional conditions.
The effects of NPY on lipolysis appear to be highly
dependent on other cellular factors influencing β-
adrenergic stimulation in the adipocyte. In one study,
NPY was shown to have no effect on lipolysis in differ-
entiated 3 T3-L1 cells under basal conditions, but aug-
mented β-adrenergic-mediated stimulation of lipolysis
[54]. When cells were pretreated with isoproterenol (10
nM; β-adrenergic agonist) and/or forskolin (activates
adenylyl cyclase to raise intracellular cyclic adenosine
monophosphate; cAMP), NPY treatment had no effect on
forskolin-induced lipolysis, but increased isoproterenol-
induced lipolysis by 30%, suggesting that NPY’s effect oc-
curred upstream of adenylyl cyclase activation [54]. To
explain why results differed from previous reports of
NPY’s inhibitory effects on lipolysis in cultured adipocytes
[14,55,56], it was suggested that NPY’s effect on lipolysis
depends on the magnitude of β-adrenergic and lipolytic
stimulation by other factors. For example, when concen-
trations of isoproterenol increased, NPY blunted rather
than augmented the stimulation of lipolysis, thus suggest-
ing that perhaps under conditions of strong and weak
stimulation of lipolysis, NPY has an inhibitory and stimu-
latory effect, respectively [54]. Consistent with other stud-
ies, the effects of NPY on lipolysis were shown to occur
through NPYR1, and it was suggested that differential ef-
fects of NPY on lipolysis occurring through the same
receptor are due to differences in receptor coupling to dif-
ferent secondary messengers, with inhibitory and stimula-
tory effects on lipolysis occurring through decreases in
cAMP and increases in calcium, respectively [54]. That
NPY and NE are co-stored and secreted by postsympa-
thetic nerve terminals in adipose tissue provides an
additional layer of complexity to the understanding of
how the different systems interact to regulate energy
metabolism in adipose tissue [54]. Thus, NPY’s effects
on lipolysis can be modulated by nutritional status, ad-
renergic activity, and changes in receptor activity to
achieve tight regulation of energy balance based on en-
ergy demand, with differences between visceral and
subcutaneous fat.
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lated to SNS output and as described above, NPY may
influence angiogenesis, adipogenesis, lipolysis, and
hypertrophy in WAT. Obesity is characterized by WAT
hypercellularity and hypertrophy, particularly in visceral
fat, and changes in SNS activity, consistent with en-
hanced lipid storage and reduced oxidation [57,58]. The
decreased SNS outflow observed in some obesity models
may stimulate WAT hyperplasia, based on experiments
showing that sympathetic nerve denervation induces cel-
lular proliferation in adipose tissue and NE treatment in
cell culture reduced preadipocyte proliferation, an effect
that was blunted by the β-adrenoceptor antagonist pro-
pranolol [59,60]. Although mechanisms of NPY’s role in
hyperplasia are not as well studied, it was shown that
through NPYR1, NPY stimulated mouse and rat preadi-
pocyte proliferation via activation of the extracellular
signal-regulated kinase (ERK) 1/2 signaling pathway
[33]. In high-fat diet-fed mice that were exposed to cold
stress for 2 weeks, there was an increase in the number
of small adipocytes (<10 μM) that were immunoreactive
for both NPYR2 and cell proliferation markers, suggest-
ing that NPY plays a role in inducing hyperplasia via
NPYR2. Similarly, co-culture of 3 T3-L1 preadipocytes
or endothelial cells with sympathetic neuron-derived
tumor cells (tyrosine hydroxylase-positive) up-regulated
expression of NPYR2 and induced proliferation in both
the endothelial cells and preadipocytes, and enhanced
differentiation of preadipocytes into adipocytes [30]. En-
hanced differentiation was associated with increased
lipid accumulation and secretion of leptin and resistin.
These effects were blocked by treatment with a NPYR2
receptor antagonist, suggesting that in adipose tissue,
SNS-derived NPY modulates proliferation, adipogenesis
and angiogenesis via up-regulation of NPYR2 [30].
The SNS innervation to WAT is known to play three
major functions including the regulation of lipolysis, cel-
lular proliferation and protein/peptide secretion [47].
Catecholamines (especially NE) are potent lipolytic fac-
tors acting through β-adrenergic receptors, which then
activate the cAMP – protein kinase A (PKA) signaling
cascades. Sympathetic neuron and adipocyte co-culture
studies indicated that NPY secreted from sympathetic
neurons inhibited β-adrenergic-mediated lipolysis [44],
although as discussed above, NPY treatment could elicit
different effects on lipolysis depending on the combin-
ation of other factors present in the cell culture model
[54]. Cross-talk between adipocytes and SNS neurons
are thus mediated by multiple signals and NPY may
modulate β-adrenoceptor-mediated lipolysis and adipo-
kine secretion. Surgical sympathetic nerve denervation
increased the numbers of bromodeoxyuridine-labeled
cells that were also immunoreactive for a preadipocyte-
specific membrane protein 3 (AD-3), indicating a specificincrease in preadipocyte proliferation [61,62]. Decreased
sympathetic drive to WAT resulted in WAT expansion
that was associated with decreases and increases in β-
adrenergic and α2-adrenergic receptor numbers, respect-
ively [63].
An in vitro study demonstrated that epinephrine (EPI)
enhanced the expression of NPY and its receptors in
murine embryonic stem cells (mESCs), and that acceler-
ated differentiation of mESCs into adipocytes was associ-
ated with increased expression of preadipocyte factor 1
(PREF-1), fatty acid-binding protein 4 (FABP4) and per-
oxisome proliferator-activated receptor γ (PPARγ) [64].
These effects were blocked by treatment with NPYR1, 2
and 5 antagonists [64]. The effect of EPI-mediated NPY
up-regulation was believed to be associated with greater
DNA methylation at the nerve growth factor responsive
element and calmodulin-responsive element sites of the
NPY gene promoter region [64]. While cell culture-
based studies have shown a strong effect of EPI on lip-
olysis, it has been demonstrated in-vivo that adrenal
medullary-derived EPI likely is a minor contributor to
whole-body adipose lipolysis, with the majority con-
trolled by SNS-derived NE, as reviewed by [65].
NPY reduces brown adipose tissue deposition and
activation
Brown adipose tissue is almost exclusively under SNS in-
nervation. The release of norepinephrine (NE) from SNS
terminals stimulates β3-adrenergic receptor-activated
BAT thermogenesis [66]. Central administration of NPY
in rats inhibited BAT thermogenesis through guanosine
diphosphate binding reduction (an indicator of brown
fat thermogenic activity) to BAT mitochondria, and
stimulated WAT lipid storage by enhancing lipoprotein
lipase (LPL) activity, which is a rate-limiting step in cata-
lyzing hydrolysis of plasma lipoproteins into free fatty
acids for uptake into peripheral tissues [67]. Despite
ample evidence that NPY reduces BAT-associated
thermogenesis, it was not until recently that our under-
standing of the involvement of various CNS-specific nu-
clei/subnuclei was revealed. Chao et al. demonstrated
the role of hypothalamic dorsomedial NPY in adipose
tissue function [68]. Knockdown of NPY expression
using adeno-associated virus-mediated RNAi in the dor-
somedial nucleus (DMN) of rat hypothalamus promoted
development of brown adipocytes in inguinal white adi-
pose tissue or transformation from WAT to BAT (also
known as brown-in-white, beige or brite cells) character-
ized by increases in mitochondrial UCP1 and peroxi-
some proliferator activated receptor-γ coactivator −1 α
(PGC1α) expression, when measured at 16 weeks post
treatment. This led to increased BAT activity and
thereby enhanced energy expenditure and cold-induced
thermogenesis [68]. The inducible nature of brown
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sible anti-obesity target and these data show that effects
of hypothalamic NPY on brown fat include both inhib-
ition of brown fat thermogenesis and effects on recruit-
ment of brown adipocytes within white adipose depots.
These studies are also fascinating because they provide
more insight into the physiological function of specific
hypothalamic nuclei, such as the DMN.
Other studies using mouse models in which NPY was
either overproduced in the ARC of wild type mice or se-
lectively reintroduced into the ARC of otherwise NPY-
deficient mice, together with NPY receptor knockout
mice, indicated that overexpression of ARC NPY reduced
sympathetic outflow via NPYR1 receptor-mediated reduc-
tion in tyrosine hydroxylase (TH; an indicator of SNS out-
flow) expression in the PVN and various regions in the
brainstem. Reduced SNS innervation was associated with
the down-regulation of UCP1 expression in BAT, which
could be reversed after surgical sympathetic denervation
to BAT [69]. The ICV injection of NPY suppressed SNS
activity in a dose-dependent manner, which was followedFigure 1 Antilipolytic and adipogenic effects of NPY on white adipos
and affects β-adrenergic receptor (β1-AR, β2-AR and β3-AR; mainly through
affinity for Gαi proteins. Subsequently, this activation of inhibitory GTP-bind
AMP (cAMP) production. Decreased cellular cAMP levels inhibit protein kina
lipase (HSL). Decreased PKA activity also inhibits phosphorylation of lipid d
magnitude of lipolysis. Lipolysis is catalyzed by 3 lipases. Triacylglycerol is fi
formation of diacylglycerol (DAG) and release of a fatty acid (FA). Monoacy
and a FA. Increased hypothalamic (abbreviated as hypo in the figure) NPY
catecholamine release, mainly norepinephrine (NE), and thereby their bind
pathway-associated lipolysis. On the other hand, NPY itself in the periphera
hypothalamus-SNS-adipose tissue axis, reduced NE enhances adipogenesis
by adrenal medullary catecholamines, primarily epinephrine (EPI), which was
Parts of the figure are adapted from references [71,72]. “→”: stimulatory effect
effect of EPI secretion.by a gradual recovery. Unilaterally microinjecting NPY
into the paraventricular nucleus (PVN) suppressed the
SNS, and the opposite was observed after medial preoptic
area microinjection. No effect was observed with injec-
tion into the anterior hypothalamic area, ventromedial
nucleus (VMN), or lateral hypothalamus (LH) [70]. Re-
duced SNS outflow decreases release of NE from sympa-
thetic nerve endings and inhibits the thermogenic
function of brown adipose tissue (BAT) by deactivating
the cAMP-dependent PKA pathway, which further
down-regulates UCP1-associated thermogenesis.
Taken together, these data indicate that NPY promotes
positive energy balance by stimulating adipogenesis and
inhibiting lipolysis in WAT. Increased thermogenesis in
brown fat and recruitment of brown adipocytes in white
adipose tissue after NPY suppression suggests that the
NPY system also has an inhibitory effect on BAT activity.
These effects appear to be mediated through the regula-
tion of the hypothalamus-SNS-adipose tissue axis. The
possible mechanisms described above are summarized in
Figures 1 and 2.e tissue. In the peripheral system, NPY binds to receptors 1, 2 and 5
β2-AR) configuration, the modification thereby leading to improved
ing protein alpha subunit (Gαi) inhibits adenylyl cyclase (AC) and cyclic
se A (PKA), which phosphorylates and activates hormone-sensitive
roplet-associated protein perilipin (peri) into PeriA, which controls the
rstly hydrolyzed by adipocyte triglyceride lipase (ATGL) resulting in the
lglycerol lipase (MGL) catalyzes hydrolysis of MAG, yielding glycerol
inhibits sympathetic nerve system (SNS) outflow and suppresses
ing to β-adrenergic receptors, which in turn reduces the cAMP-PKA
l system can stimulate ERK-mediated adipogenesis. Through the
via undefined mechanisms. Reduced SNS outflow is compensated for
also known to stimulate adipogenesis, possibly through NPY regulation.
; “⊣”: inhibitory effect ;“······›”mechanisms unknown; “─··─·›” compensatory
Figure 2 NPY inhibits BAT thermogenesis via reduced SNS outflow. Increased release of NPY in the hypothalamus inhibits sympathetic
nerve system (SNS) outflow, particularly norepinephrine (NE) release. Consequently, it inhibits the cAMP-PKA signaling pathway via β-adrenergic
receptors. Reduced lipolysis decreases the level of fatty acid storage in the brown adipose tissue, together with reduced uncoupling protin 1
(UCP1) expression and secretion, resulting in reduced thermogenic potential. Consequently, with less fatty acids being transported into the
mitochondria by the carnitine palmitoyl transferase (carnitine shuttle) and also reduced UCP1 functioning to dissipate the proton-motive force
across the mitochondrial membrane, there is less heat production. Part of the picture is summarized from [73].
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The NPY system represents a form of communication
between the hypothalamus and adipose tissue, and is
linked to positive energy balance through increases in
energy intake and storage and reduced energy expend-
iture. This is achieved indirectly through bidirectional
neuronal and hormonal communication, and possibly
via direct circulation through the blood brain barrier.
The hypothalamus is the energy sensory center for
signals produced by peripheral tissues such as the
gastrointestinal tract and adipose tissue. Hypothalamus-
mediated white and brown adipose tissue turnover is
mainly regulated through SNS outflow, as summarized
above. The study of the role of specific hypothalamic nu-
clei in the regulation of peripheral adiposity did not re-
ceive much attention until recently, partly due to
advents in molecular technology as well as a better un-
derstanding of brain neural circuits. A body of evidence
has shown that NPY in the ARC, PVN, and DMN neu-
rons is involved in adiposity and BAT thermogenesis
through regulation of the SNS outflow [68,69]. Whether
other hypothalamic nuclei play the same role remains
elusive.While early studies revealed that adipose tissue was in-
nervated by the sympathetic nervous system, they did
not reveal the specific brain nuclei from which the SNS
outflow to WAT originated. A transneuronal tract tracer,
a pseudorabies virus (PRV), was used for this purpose,
because it is a neurotropic virus that binds to the pre-
synaptic neural membrane, fuses with the axon mem-
brane, and then delivers uncoated capsids in the axon
(described in an excellent review by [47]). The capsids
are then transported to the cell body where they repli-
cate and can exit the infected cell via the dendrites,
thereby only infecting neurons that are synaptically con-
nected to those PRV-containing cells [47]. Immunostain-
ing after PRV injection into fat revealed that in
hamsters, regions of the hypothalamus including the
ARC, dorsal, lateral, suprachiasmatic, PVN, and nuclei
and medial preoptic area, were identified as sites that
modulated SNS outflow to the WAT [47]. Hypothalamus-
SNS-BAT circuitries were demonstrated to be hyperactive
in the PVN, DMN, LH, anterior hypothalamic nucleus,
and posterior hypothalamic nucleus [74]. Whether adi-
pose tissue is also under the control of the parasym-
pathetic nervous system is still controversial [75,76].
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posity and brown fat thermogenesis may provide better
targets toward the control of overweight and obesity
through the manipulation of the hypothalamus-adipose
tissue axis, and allow for development of more pathway-
specific therapeutic strategies.
Adipose tissue not only dynamically accumulates and
releases lipids, but also serves as an endocrine organ that
produces adipokines, hormones, and appetite-regulating
factors as the sensory input reflecting the amount of
lipid and adipocyte turnover. Sensory information is
transported via dorsal root ganglion to the spinal cord
and then on to the brain to interact with the SNS out-
flow to the adipose tissue [47,74,77]. The sensory innerv-
ation of adipose tissue may serve as a feedback loop to
regulate the level of its sympathetic drive and also regu-
late adipocyte turnover [78]. Sensory information in-
cludes adipokines such as adiponectin, apelin, resistin
and leptin, that all target various regions in the hypo-
thalamus and regulate body energy homeostasis [79].
Leptin is one of the best studied adipokines that informs
the brain of body fat levels. Treatment of human ab-
dominal subcutaneous adipocytes with recombinantFigure 3 Role of NPY in energy intake and expenditure. cNPY: NPY in
barrier; Hypo: hypothalamus. The cNPY stimulates food intake mainly via N
hypothalamus-SNS-adipose axis, NPY reduces sympathetic nervous system
by enhancing adipogenesis and inhibiting lipolysis, as well as inhibiting bro
thermogenesis. The same effects in WAT were achieved by peripheral NPY via
adipose tissue. Adipose-hypothalamus crosstalk serves as a feedback loop via
status so that the brain can make the necessary adjustment. Numerous adipo
that play an important role in adjusting energy balance through the hypotha
through SNS outflow, such as leptin, NPY, and UCP1. NPY is more abundant i
Whether and how it crosses the blood brain barrier is critical for understandinhuman NPY reduced leptin secretion but did not affect re-
lease of adiponectin and tumor necrosis factor α [31].
Interestingly, high fat diet-induced diabetic mice subjected
to intra-abdominal UCP1 overexpression using an adeno-
viral vector had significantly reduced food intake charac-
terized by reduced NPY mRNA in the hypothalamus, and
improved insulin and leptin sensitivity. Local nerve dissec-
tion showed that these actions were achieved by afferent-
nerve signals from intra-abdominal fat tissue to the
hypothalamus that modulated hypothalamic leptin sensi-
tivity, illustrating the importance of the hypothalamus-
adipose tissue feedback loop [80]. This may suggest that
brown adipocytes in WAT play an important role in
whole-body energy metabolism and ectopic UCP1 expres-
sion could be a promising future research direction. In
summary, an adiposity negative-feedback model indicates
that adiposity signals can inform the brain of changes in
body fat mass so that the brain can mount adaptive adjust-
ments in energy intake to stabilize fat stores in the long
term. Understanding the neural signaling pathways and
endocrine regulation associated with the adiposity nega-
tive feedback may provide a new avenue for treatment of
obesity and associated diseases.the central nervous system; pNPY: Peripheral NPY; BBB: Blood brain
PYR1 and NPYR5 to increase energy intake. Additionally, through the
(SNS) outflow, which promotes white adipose tissue (WAT) deposition
wn adipose tissue (BAT) deposition and associated nonshivering
different signaling pathways. This collectively leads to energy storage in
sensory inflow that informs the brain of the long-term peripheral energy
kines, hormones, and appetite regulating factors have been identified
lamus either by directly affecting food intake or regulating adiposity
n the central nervous system as compared to the peripheral system.
g its role in energy regulation.
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NPY is expressed in both the hypothalamus and periph-
ery and is detected in the circulation. Understanding the
cellular sources, routes of delivery to various tissues and
the rate of decay are critical for understanding the
physiological roles of NPY. The majority of NPY is se-
creted by the neurons in the CNS with lower concentra-
tions in the peripheral system. In the SVF fraction of
adipose tissue from mice, secreted NPY was reported to
be in the picomolar range, consistent with physiological
concentrations in humans [29]. Recent studies showed
that the concentration of cerebrospinal fluid (CSF) NPY
(cNPY; 792.1 pg/mL) was 3 fold greater than plasma
NPY (pNPY; 220.0 pg/mL) in humans [81]. Therefore,
whether hypothalamus-derived NPY can enter the blood
stream is critical in understanding the regulation of food
intake and fat deposition. A clinical study demonstrated
that circulating NPY in obese women was elevated as
compared to women from the control group [82]. How-
ever, no statistically significant cross-correlations have
been identified between CSF and plasma NPY in healthy
males. Circulating NPY was also elevated in genetically
obese mice [30]. The cNPY/pNPY ratio depends on the
rates of NPY production, degradation, reabsorbtion in
both compartments and potential transport across the
blood brain barrier. Although NPY was shown to cross
the blood–brain barrier intact via a non-saturatable
transporter in rats, which is still unidentified in humans
[83], the absence of cross-correlation between CSF and
plasma may be due to local protease degradation as indi-
cated by Baker et al. [52]. As a peptide, the active win-
dow of time for NPY is short as compared to a steroid
neurotransmitter. Ahlborg et al. showed that in adult
men the half-life for NPY is up to 39 min [84]. The con-
centration of NPY in both central and peripheral compart-
ments has a higher heritability than other neuropeptides
[85,86], which makes it an attractive candidate for re-
search on genetic aspects of metabolic diseases. Thus, a
further understanding of factors governing NPY concen-
trations and transport in the circulation and between cen-
tral and peripheral systems, especially in humans, will rely
on more research together with advanced techniques that
are sensitive to lower concentrations of NPY.
Conclusions and implications
Neuropeptide Y stimulates food intake and white fat de-
position and at the same time reduces brown fat activa-
tion and consequently thermogenesis, yielding a net
accumulation of energy via enhanced energy intake and
storage (Figure 3). The function of NPY is determined
by site-specific NPY and NPY receptor-subtype expres-
sion, NPY release, degradation, and concentrations in
the circulation, all of which are regulated by numerous
energy balance strategies. This provides tight regulationof an essential system to ensure that the NPY signals can
respond rapidly and for prolonged durations during
short and long-term control of energy homeostasis in
various food-accessible conditions. Understanding the
role of NPY in energy homeostasis has critical implica-
tions for biomedical applications, the most common
pharmacological therapies nowadays for obesity involv-
ing gastrointestinal surgery and pharmacological inter-
ventions. Drugs that are intended for weight loss affect
either metabolism by reducing absorption of nutrients
from food or through the CNS by decreasing appetite
and increasing energy expenditure. In light of the pur-
ported systemic role of NPY, it becomes a promising
candidate for controlling the development and treatment
of obesity. Whether NPY can be used as a biomarker for
obesity awaits further determination. A body of studies
aimed to manipulate NPY and NPY receptor-subtype
function highlight the feasibility of targeting the NPY
system for therapeutic strategies. However, the mecha-
nisms underlying the effects of NPY are complicated, es-
pecially in view of brain-adipose cross talk.
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